ClinicalTrials.gg
RecruitingNCT05840549CO-STARUpdated Sep 1, 2023

A Study Comparing Urolift and TURP Ahead of Radiotherapy in Men With Urinary Symptoms Secondary to Prostate Enlargement

An interventional study of TURP and UroLift in Prostate Cancer, sponsored by Royal Marsden NHS Foundation Trust. Recruiting at 3 sites in United Kingdom. Open to male participants. Per ClinicalTrials.gov, last updated 2023-09-01.

Sponsored by Royal Marsden NHS Foundation Trust · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 6 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust — 8 open to participants now, 10 under way, 1 of them phase 3. Prostatic Neoplasms · Royal Marsden NHS Foundation Trust.

Planned enrollment
10th of 14
45 · median 81
Started
2023
with 1 other
No phase
9 of 21
4 open now
Registered
13th of 21
by date

Among the 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust, this one is the 10th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2023, is one of 9 with no phase, and was the 13th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

8 of the 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust, or all of them as a file.
02

Study summary

Prostate cancer affects 1 in 8 men and in the UK approximately 14,000 men are treated with radiotherapy.

Around half of men diagnosed with prostate cancer will also have an enlarged prostate making it difficult to pass urine. When having radiotherapy, the prostate swells further which can lead to complete blockage of urine flow (urine retention), sepsis and kidney failure in severe cases. Radiotherapy itself can also cause urinary symptoms meaning that some patients can continue to have difficulty passing urine long after their cancer treatment finishes. Around a third of patients will need an operation to shrink their prostate before radiotherapy to prevent these possible short and long-term problems.

The standard operation is a transurethral resection of prostate (TURP). This involves cutting a channel through the prostate to improve urine flow.

This will be compared with a newer procedure known as UroLift. During UroLift, clips are inserted into the water pipe to pin back the prostate to widen the channel and improve urine flow. Which treatment is more acceptable to patients and gives better outcomes has never been tested before in men having radiotherapy for prostate cancer.

The study will help us to understand how the treatments impact on a patient's quality of life and understand what matters most to patients.

The results of this feasibility study will help us design a bigger study to assess TURP and UroLift in a larger group of patients across different hospitals. This research will help future patients make decisions about prostate cancer treatment choices that can affect their long-term well-being.

Read the detailed description

Prostate radiotherapy can cause lower urinary tract symptoms (LUTS) such as urinary frequency, difficulty starting a urine stream or feelings of incomplete emptying. 50% of men aged over 60 years may have pre-existing LUTS from bladder outflow obstruction (BOO) due to prostatic enlargement.

The short-term complications of untreated BOO in the context of prostate radiotherapy, although relatively rare, can be disastrous, leading to urinary retention, sepsis and renal failure. In the long-term, urinary symptoms and complications can continue to worsen. Patients with low flow rates pre-radiotherapy are at highest risk of urinary retention and are often offered transurethral resection of prostate (TURP) prior to radiotherapy. An urgent transurethral resection of prostate (TURP) either during or post radiotherapy may significantly disrupt the completion of the treatment and compromise outcomes, both oncological and functional. Case studies suggest that when patients undergo a TURP to treat prostate enlargement after radiotherapy, the risk of incontinence is much higher than surgery before radiotherapy. Therefore, for radiotherapy to safely go ahead, BOO due to an enlarged prostate must first be addressed. UroLift is a newer, minimally invasive alternative to TURP, approved by NICE for use in BPH and available in over 100 trusts nationally. A growing body of evidence including three meta-analyses supports its use in benign disease.

UroLift has not been trialled in patients undergoing prostate radiotherapy with coexisting LUTS. A subgroup analysis performed on retrospective data suggested that patients who had previously undergone prostate radiotherapy experienced symptom relief without an increase in adverse events.

The purpose of this trial is to produce a protocol for a randomised controlled evaluation of clinical and cost effectiveness of UroLift in comparison to TURP for men due to receive radiotherapy as treatment for prostate cancer. At the end of this study, we will understand whether such a trial is acceptable to all stakeholders, is methodologically robust and thus feasible. Furthermore, we will be able to report pilot findings for safety and efficacy

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men undergoing prostate radiotherapy for prostate cancer
  • Patients with moderate to severe and/or bothersome lower urinary tract symptoms secondary to prostate enlargement and/or an obstructive flow rate
  • Patients willing and able to provide written for the study.

Exclusion criteria

Exclusion Criteria:

  • Extensive locally advanced disease
  • Unfavourable anatomical features (e.g. large middle lobe, for UroLift this requires advanced techniques that have not been fully evaluated in the benign setting(11)
  • Prostates over 100g (as per manufacturer's guidelines)
  • Co-morbidities precluding surgical intervention
  • Prior prostate cancer treatment (including radical prostatectomy, focal therapy i.e. brachytherapy / high intensity focal ultrasound)
  • Prior surgical intervention for benign prostatic hyperplasia (including prior UroLift / TURP / other prostate de-obstructing procedures)
  • Urinary symptoms not due to prostatic enlargement as primary cause (i.e. neurological disease)
  • Patients with complications of prostate enlargement including catheter dependent retention, recurrent urinary tract infections, bladder stones, obstructive uropathy
  • Urinary incontinence due to an incompetent sphincter
  • Co-existing gross haematuria
  • Current active urinary tract infection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Active comparator
    TURP

    Transurethral Resection of Prostate

    Procedure: TURP

  • Experimental
    UroLift

    UroLift

    Procedure: UroLift

Interventions

  • ProcedureTURP

    TURP is an operation which can be performed under a general / regional anaesthetic. A cystoscope is passed into the urethra meatus, along the length of the urethra to the level of the prostate. The obstructing prostate lobes are resected using mono polar or bipolar energy to create a channel for improved urinary flow. Haemostasis is achieved by coagulation followed by insertion of a catheter for irrigation post procedure. Generally, patients stay for 1-2 nights post operatively. On the day of discharge the catheter is removed.

  • ProcedureUroLift

    UroLift (Neotract) is a NICE-approved alternative to TURP that can be performed under local anaesthetic, sedation or general anaesthetic. The system comprises of two single-use components, a delivery device and an implant. The implant is made of a nitinol capsular tab, a polyethylene terephthalate monofilament and a stainless-steel end-piece. Again, a modified cystoscope is passed into the urethral meatus, along the length of the urethra to the level of the prostate. The delivery device deploys the implants into the prostate to 'pin' back the lobes of the prostate to create a channel for improved flow. Typically, 2-4 implants are used per procedure. Nine out of ten patients do not require a catheter post procedure

06

What researchers measure

Primary outcomes

  1. Recruitment rate (number of patients enrolled)

    We will evaluate whether it is possible to recruit patients to an RCT comparing standard treatment with a new treatment untested in the cancer arena

    Time frame: Number of patients recruited measured at 3 months

  2. Recruitment rate (number of patients enrolled)

    We will evaluate whether it is possible to recruit patients to an RCT comparing standard treatment with a new treatment untested in the cancer arena

    Time frame: Number of patients recruited measured at 6 months

  3. Recruitment rate (number of patients enrolled)

    We will evaluate whether it is possible to recruit patients to an RCT comparing standard treatment with a new treatment untested in the cancer arena

    Time frame: Number of patients recruited measured at 9 months

  4. Recruitment rate (number of patients enrolled)

    We will evaluate whether it is possible to recruit patients to an RCT comparing standard treatment with a new treatment untested in the cancer arena

    Time frame: Number of patients recruited measured at 12 months

  5. Retention rate

    We will assess the proportion of patients who will complete the trial protocol

    Time frame: End of study (24 months)

Secondary outcomes

  1. Acceptability of intervention

    The Research Team will carry out 12 in-depth interviews. Using the Theoretical Framework of Acceptability(19), affective attitudes, burden, ethicality, intervention coherence, opportunity costs and perceived effectiveness will be assessed

    Time frame: End of study (24 months)

  2. Change from baseline in patient reported outcomes as assessed by the Extended Prostate Cancer Index Composite-50 (EPIC-50)

    The EPIC-50 is a validated questionnaire for measuring health related quality of life

    Time frame: Baseline, 6 weeks and three months post intervention

  3. Change from baseline in patient reported outcomes as assessed by the UCLA Prostate Cancer Index (UCLA-PCI)

    The UCLA-PCI is a validated questionnaire for measuring health related quality of life

    Time frame: Baseline, 6 weeks and three months post intervention

  4. Change from baseline in patient reported outcomes as assessed by the International Consultation on Incontinence Questionnaire-Urinary Incontinence (ICIQ-UI)

    The ICIQ-UI is a validated questionnaire s a questionnaire for evaluating the frequency, severity and impact on quality of life (QoL) of urinary incontinence

    Time frame: Baseline, 6 weeks and three months post intervention

  5. Change from baseline in patient reported outcomes as assessed by the EuroQol EQ-5D

    The EQ-5D is a validated questionnaire for measuring health related quality of life

    Time frame: Baseline, 6 weeks and three months post intervention

  6. Change from baseline in patient reported outcomes as assessed by the Couples Illness Communication Scale (CICS)

    The CICS is a validated questionnaire for assessing illness-related couple communication

    Time frame: Baseline, 6 weeks and three months post intervention

  7. Change post surgery & post radiotherapy in patient reported outcomes as assessed by the patient global impression of improvement (PGI)

    The PGI is a validated single item self reported scale to assess patient reported post-operative improvement in condition

    Time frame: 6 weeks and three months post intervention

  8. Change from baseline in patient reported outcomes as assessed by the International Prostate Symptom Score (IPSS)

    The IPSS is a validated questionnaire for measuring the severity of urinary symptoms and overall quality of life

    Time frame: Baseline, 6 weeks and three months post intervention

  9. Post treatment functional assessment of cancer therapy prostate (FACT-P)

    The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain. Total subscale score range for physical well-being domain is from 0 (worst response) to 28 (best response), where higher score indicate better quality of life.

    Time frame: Three months post intervention

  10. Health related quality of life questionnaires

    collected and assessed for appropriateness, usability and completeness for both arms 3 months post radiotherapy treatment

    Time frame: End of study (24 months)

  11. Safety

    30 day surgical morbidity rates will be collected with respect but not limited to infection, urinary retention and bleeding.

    Time frame: 30 days post surgery

  12. Efficacy of procedure

    Improvement in baseline IPSS score

    Time frame: End of study (24 months)

  13. Efficacy of procedure

    Improvement in baseline Urine flowmetry (measured by increased maximum flow rate)

    Time frame: End of study (24 months)

  14. Efficacy of procedure

    Improvement in baseline Urine flowmetry (measured by post void residual)

    Time frame: End of study (24 months)

  15. Cost of intervention

    Information on costs of the two interventions

    Time frame: End of study (24 months)

  16. Re-Operation rate

    Rate of re-operation for technical failure to reduce outflow obstruction

    Time frame: End of study (24 months)

07

Study locations

2 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for May 2024, 12 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 12 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2023
First posted
May 3, 2023
StartActual
May 9, 2023
Primary completionEst.
May 9, 2024
CompletionEst.
May 9, 2025
Last update
Sep 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05840549
Collaborators
King's College London, St George's University Hospitals NHS Foundation Trust, Institute of Cancer Research, United Kingdom, North Cumbria University Hospitals NHS Trust, University College, London, City, University of London
Responsible party
Sponsor
First posted
May 3, 2023
Start date
May 9, 2023
Primary completion
May 9, 2024 (estimated)
Completion
May 9, 2025 (estimated)
Last update
Sep 1, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion